News headlines about Verastem (NASDAQ:VSTM) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Verastem earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.5552597718765 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- FDA Accepts New Drug Application for Duvelisib and Grants Priority Review (markets.financialcontent.com)
- Stock’s Risk Factors’ Secrets – Verastem Inc (NASDAQ: VSTM) (stocktradingpoint.com)
- Verastem (VSTM) PT Set at $17.00 by Cantor Fitzgerald (americanbankingnews.com)
- Verastem, Inc., (NASDAQ: VSTM) – An Eye on Average True Range (ATR) (stocksnewstimes.com)
- Radar for In Play Stock – Verastem Inc (NASDAQ: VSTM) (stockspen.com)
Shares of VSTM stock opened at $2.96 on Monday. Verastem has a fifty-two week low of $1.61 and a fifty-two week high of $5.71. The stock has a market cap of $150.37, a PE ratio of -1.68 and a beta of 2.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.13 and a current ratio of 5.13.
Several equities analysts have issued reports on VSTM shares. Cann reiterated a “buy” rating and issued a $15.00 target price (up previously from $6.00) on shares of Verastem in a research note on Sunday, December 10th. Cantor Fitzgerald set a $17.00 target price on Verastem and gave the company a “buy” rating in a research note on Sunday, December 10th. HC Wainwright set a $10.00 target price on Verastem and gave the company a “buy” rating in a research note on Wednesday, December 13th. Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research note on Monday, December 11th. Finally, Zacks Investment Research lowered Verastem from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.14.
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.